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Progression of chronic renal failure is related to glucocorticoid
production
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Progression of chronic renal failure is related to glucoeorticoid produc-
tion. Progression of chronic renal failure during 35 treatment periods in
27 patients was measured as the rate of change of bimonthy radioiso-
tope GFR for an average of 15 months. Treatments were comprised of:
(1) mild protein restriction; (2) more severe protein and phosphorus
restriction plus essential amino acids; or (3) the same diet pitis keto-
acids, Progression was significantly (P < 0.025) correlated with urinary
17-hydroxycorticosteroid excretion in all three treatment groups; over-
all r was 0.78 (P < 0.0001). Multiple regression analysis showed that the
following factors were not additional significant determinants of pro-
gression: urea N excretion, phosphate excretion, protein excretiOn,
serum calcium times phosphorus product, serum alkaline phosphatase,
serum uric acid, serum triglycerides, serum cholesterol, etiology, mean
arterial pressure, or enalapril treatment. However, when urinary 17-
hydroxycorticosteroid excretion was factored by GFR (with which it
was correlated), additional significant regressors appeared: serum tri-
glycerides and polycystic kidney disease, which tended to be atsociated
with more rapid progression, and ketoacid treatment, which tended to
be associated with slower progression. Mean 17-hydroxycorticosteroid
excretion differed significantly between the three treatment groups, in
the order (1)> (2) > (3) (though not when factored by GFR). Changing
from essential amino acids to ketoacids (or vice versa) without change
in diet was associated with lower 17-hydroxycorticosteroid excretion
on ketoacids (but not when factored by GFR). Therefore, progression
of chronic renal failure is related to glucocorticoid production (and to
triglyceridemia, which is correlated with it). Ketoacids appear to slow
progression in part by suppressing production of glucocorticoids.
Since the first anecdotal evidence [1] that nutritional therapy
may slow progression of chronic renal failure, there has been
growing interest in two possibilities: (1) that a common mech-
anism causes progression of many types of chronic renal
failure; and (2) that this process can be slowed or arrested by
diet or drugs.
Many such mechanisms have been postulated, based on
experiments in animals and/or clinical observations. Factors
proposed to contribute to progression include arterial pressure
[2], and more specifically glomerular capillary pressure [31,
which is reduced by angiotensin-converting enzyme inhibitors
[4], serum calcium times phosphorus product [5, 6], urinary
phosphorus excretion [7], protein intake itself [8], hyperurice-
mia [9], hypertriglyceridemia [10], hypercholesterolemia [11],
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and hyperoxalemia [121. As yet, no studies have examined the
influence of such factors acting in concert on progression.
Ketoacid mixtures, administered in conjunction with a low
protein, low phosphate diet, have been reported to slow pro-
gression in several studies [13—15], though not in all [16]; in
niost of these reports no attempt was made to diffetentiate
between the effects of the diet and the ketoacids. Recently, we
have reported [17] that some patients who were on the low
protein, low phosphate diet supplemented with essential amino
acids exhibited slowed or arrested progression when changed to
ketoacids, suggesting a specific effect of ketoacids on progres-
sion of chronic renal failure.
Previously we have reported that branched chain ketoacids,
especially 2-ketoisocaproate, exert protein sparing effects [18—
20]. One way in Which these two different effects of ketoacids
might be related is suppression of glucocorticoid production.
Glucocorticoids play a role in the regulation of protein turnover
[21, 22]. Even though they are often used therapeutically in
chronic renal disease, it is conceivable that their beneficial
immunological effects at high dosage might obscure a deleteri-
ous effect on progression within the physiological range of
hormone production, mediated perhaps by an effect on renal
protein turnover.
In the present study this hypothesis was tested by measuring
progression in patients with renal failure, and relating it to some
of the above-mentioned factors postulated to contribute to
progression and to glucocorticoid production. The latter was
measured as 24-hour urinary excretion rate of 17-hydroxycor-
ticosteroids [23].
Methods
Multiple regression analysis of the factors determining pro-
gression rate was performed, based on longitudinal observa-
tions during 35 treatment periods lasting an average of 15
months, in 27 patients (17 males and 10 females) with chronic
renal failure. Age varied from 23 to 78 years (mean 51 years).
Diagnoses were: diabetic nephropathy, 6; glomerulonephntis,
10; interstitial nephritis, 4; polycystic kidney disease, 4; un-
known, 3. Patients with IgA nephropathy were excluded be-
cause of the variable course of this disorder [24, 25]. Four
patients were treated by mild protein restriction alone. The
other 23 were prescribed a diet [17] containing 0.3 g per kg ideal
weight of protein and 7 to 9 mg per kg ideal weight of
phosphorus, supplemented with vitamins. However, 24-hour
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Table 1. Summary of patients studied
Pt Rxa Sex Dx"
Mean
I7OHCS
excretion
mg/day
GFR, mi/rn/n
First Last
No. of
GFR's
Rate of
change of
GFR
mi/rn/n/month
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
K
K
A
K
A
K
A
K
K
K
A
K
A
K
K
A
N
N
N
A
A
A
K
A
K
N
A
K
K
A
A
K
A
K
A
F
M
M
F
F
F
M
M
M
M
M
M
M
F
M
M
M
F
M
M
M
M
M
F
F
F
F
D
U
G
G
P0
I
G0
D
Cl
D
P
G
U
D
D
U
I
I
I
G
P
G
D
P
G
3.00
5.13
5.47
2.68
3.65
1.75
8,38
2.73
2.90
2.37
5.25
3.70
3.30
3.18
2.20
3.68
10.00
2.80
4.20
3.37
3.60
2.90
2.17
3.15
2.60
4.16
6.77
5.60
3.65
2.90
3.30
2.43
4.13
3.74
2.15
7.6 6.6
5.0 2.8
7.4 3.5
3.5 3.2
9.3 7.6
7.6 6.7
24.3 12.3
13.6 9.1
4.7 3.6
6.8 4.9
14.1 8.9
8.9 7.5
8.3 4.8
4.8 3.3
4.3 2.6
18.0 17.8
24.6 7.3
13.1 6.6
29.0 25.7
9.5 8.6
37.2 37.9
5.0 3.9
3.9 3.6
7.1 6.4
6.9 4.2
13.3 8.9
25.6 22.1
22.1 18.0
20.5 21.0
16.1 17.9
10.7 8.0
8.0 4.9
14,6 9.3
9.3 8.8
8.3 9.6
16
6
5
6
3
5
5
6
10
11
9
5
5
6
12
14
10
7
5
3
10
10
8
6
11
11
6
8
5
8
4
11
7
9
5
—0.058
—0.310
—0.410
—0.200
—0.290
—0.058
—0.510
—0.240
—0.046
—0.070
—0.164
—0.143
—0.303
—0.138
—0.062
—0.066
—0.740
—0.153
—0.250
—0.377
—0.250
—0.052
—0.085
—0.290
—0.012
—0.265
—0.839
—0.557
—0.260
0.190
—0.206
—0.290
—0.524
—0.200
—0.040
Mean
SEM
3.80
0.29
12.4 9.6
1.3 1.3
7.6
0.5
—0.236
0.035
a Abbreviations are: K, ketoacids; A, amino acids; N, mild protein restriction alone.
b Abbreviations are: D, diabetic nephropathy; U, unknown; G, chronic glomerulonephritis; P, polycystic kidney disease; I, interstital nephritis.
urinary urea N analyses (Table 5) showed that compliance was
poor and protein consumption was in fact higher, averaging
about 0.56 g per kg. In 16 studies, subjects received a mixture
of ketoacids and amino acids, described in detail elsewhere
[17], in a dose of 18 g per day. In the remaining 14 studies,
patients received a mixture of essential amino acids [17] in a
dose of 10 g per day. Eight patients received first amino acids
and then ketoacids. All were seen monthly or bimonthly. Blood
pressure was measured at each visit in the sitting posture by a
single observer, and averaged over the entire study. All but four
patients received anti-hypertensive drugs, including enalapnl in
five cases. Diuretics were required in all but six, sodium
polystyrene sulfonate in five, NaHCO3 in eight, and aluminum-
containing antacids in three. All received CaCO3, 2 to 3 g per
day. Twenty-four hour urine samples were obtained without a
preservative, and were kept in a refrigerator during and after
collection.
Fasting serum and 24-hour urine chemical values were mea-
sured in the Johns Hopkins Hospital Chemistry Laboratory.
17-Hydroxycorticosteroid excretion (17OHCS) was measured
in the Pediatric Endocrine Laboratory, using the Silber-Porter
method [23]. Glomerular filtration rate (GFR) was measured
bimonthly as the urinary clearance of intravenously injected
99mTc..DTPA (100 MCi), subcutaneously injected '"I-iothala-
mate (35 i.Ci), or both (in which case the two clearances were
averaged). Three collection periods were averaged. We have
previously reported that these two techniques yield nearly
identical clearances in chronic renal disease [26]. Correction for
body weight or surface area was not made. Progression was
calculated as the linear regression of GFR on time in months.
Pre-treatment values were not employed, in order to exclude
bias introduced by a possible acute decrease in GFR in re-
sponse to reduction of protein intake. The average number of
bimonthly GFR determinations was 7.6 (minimum 3). Mean
starting GFR was 12.4 ml/min (Table 1).
Serum and urine chemical values were averaged over the
entire period of observation in each subject. An average of six
measurements of I7OHCS was obtained in each subject.
The data were analyzed by multiple linear regression, using
as independent variables in the primary analysis the ten quan-
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Table 2. Mean values and ranges of independent variables examined
Variable Mean Rangea SD
17-hydroxycorticosteroid 3.80 1.75—10 1.75
excretion mg/day
Urea N excretion g/day 5.64 2.5—12.2 1.94
Phosphorus excretion mg/day 400 172—876 178
Protein excretion glday 2.09 0.2—6.7 1.81
Serum calcium times phosphorus 40 24—71 8
mg2/d12
Serum alkaline phosphatase 100 40—409 78
lU/liter
Serum uric acid mg/dl 7.6 4.6—11.5 1.5
Serum cholesterol mg/dl 201 120—276 40
Serum triglycerides mg/dl 185 82—680 118
Mean arterial pressure mm Hg 105 89—132 8
a Values shown are the average of monthly or bimonthly determina-
tions throughout the period of observation in individual studies.
tities listed in Table 2, mean GFR, age, and the following
"dummy variables", that is, variables scored as 0 or 1: sex,
ketoacid therapy, enalapril therapy and each of the four diag-
noses listed above. The 35 studies were considered as indepen-
dent observations for simplicity, even though eight patients
were studied twice. Multiple linear regression was carried out
using a stepwise technique [27]. First, the one-variable model
yielding the highest F statistic was computed. Additional vari-
ables were added one by one, using a significance level of 0.05
as a criterion for entry. After a variable was added, all variables
were reexamined and any were deleted that did not produce a F
statistic significant at the 0.05 level.
Two secondary analyses were carried out: first, 17OHCS,
urinary urea N, and urinary protein excretion were replaced by
the logarithms of these quantites, because their distributions
were not normal. Second, I7OHCS was replaced by 17OHCS
factored by GFR.
In addition, L7OHCS was measured in 11 of the 27 patients on
14 occasions when they were changed from essential amino
acids to ketoacids (or vice versa) with no change in diet. During
six of these comparisons, sufficient GFR determinations to
assess progression were not made.
Results
Simple correlation between progression rate and I7OHCS
excretion
When progression rate was examined as a function of all 19
variables, only 17OHCS was a significant regressor. This linear
relationship is shown in Figure 1 as the solid line. Furthermore,
similar linear relationships between progression and 17OHCS
were seen in each of the three treatment subgroups (Fig. 1,
Table 3).
Interrelationships between variables
As shown in Table 4, progression was also highly significantly
correlated with serum triglyceride level, which was in turn
highly correlated with 17OHCS. High rates of urinary excretion
of phosphate and urea were also associated with high values of
17OHCS and also with serum uric acid level.
GFR (average of first and last values shown in Table 1) was
negatively correlated (P < 0.05) with its rate of change. This is
because low GFR's, if associated with rapid progression rates,
make patients proceed to dialysis before a sufficient number of
GFR's can be obtained to estimate progression. Therefore,
such cases are automatically excluded, and a negative correla-
tion between GFR and progression rate inevitably results. GFR
was also correlated with urinary urea and urinary phosphate,
because patients near the end stage were in general subjected to
more rigorous dietary restriction (Table 5). A negative correla-
tion between GFR and serum calcium times phosphorus prod-
uct is to be expected. Surprisingly, serum triglycerides were
positively correlated with GFR. Other variables not shown in
Table 4 exhibited no significant correlations, except for corre-
lations between mean arterial pressure on the one hand, and age
and sex on the other.
Logarithmic transformations of independent variables
When several variables were replaced by their logarithms,
17OHCS remained the most significant variable (P 0.0001)
but urine urea N also became significant (P = 0.0386). More
rapid progression was associated with lower urinary urea N.
The explanation of this seemingly paradoxical finding is the
correlation between GFR and progression rate: less severely
affected patients ate more protein (Table 5) and also tended to
progress more rapidly, on the average, for reasons given earlier.
Effect of treatments
An analysis of variance was performed to compare mean
values of each parameter in the three treatment groups. The
results are shown in Table 5. Although mean values for GFR
and progression rate differ, these differences failed to attain
statistical difference. Serum chemical values also did not differ.
17OHCS differed significantly between the three groups, in the
order (1) > (2) > (3). Urinary urea N excretion was the same in
the two groups on a severely restricted diet [(2) and (3)1, but
was significantly higher in those on mild protein restriction
alone (1). Mean arterial pressure did not differ between the
groups.
Alternative calculation: J7OHCS factored by GFR
Since 17OHCS was correlated (r =0.40, P < 0.02) with GFR,
we were concerned that the relationship shown in Figure 1
might be attributable to decreasing renal clearance of I 7OHCS
as GFR falls. Therefore an alternative variable, 17OHCS fac-
tored by GFR, was employed in the multiple regression analysis
in place of 17OHCS. The results (Table 6) show that four
regressors are significant at the P < 0.05 level: serum triglyc-
erides, polycystic kidney disease and 17OHCS/GFR, all of
which are associated with more rapid progression, and ketoacid
therapy, which is associated with slower progression. The
overall correlation coefficient is r = 0.78, the same as the
previous analysis based on 17OHCS alone. To explore this
possibility further, the linear regression of 17OHCS on time was
calculated in each study, as GFR fell: in two studies a signifi-
cant decline in 17OHCS with time occurred, but in the other 33
studies, it did not.
Changing supplements (from amino acids to ketoacids or vice
versa) without change in diet led to significantly (P < 0.025)
lower 17OHCS (but no significant change in 17OHCS/GFR)
while on ketoacids than while on amino acids (Table 7) in 13 out
of 14 instances. Sequential measurements in one patient whose
supplement was changed three times are shown in Figure 2.
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Table 3. Correlations between progression rate and
17-hydroxycorticosteroid excretion
Treatment group b r N P
Mild protein —0.082 0.994 4 0.0005
restriction alone
Essential amino acids —0.101 0.68 15 0.0052
Ketoacids —0.102 0.76 16 0.0005
All studies combined —0.093 0.78 35 0.0001
Discussion
A relationship between progression of chronic renal failure
and endogenous glucocorticoid production has apparently not
been reported previously. The correlation found here is highly
significant statistically. It does not follow, however, that high
levels of glucocorticoids accelerate the progression of chronic
renal failure or the converse. Changes in progression and in
glucocorticoid production may both be consequences of other
unidentified variables.
Wide variation in progression rates among patients with
chronic renal failure has long been recognized but never ex-
plained. The present relationship provides clues that may prove
useful in accounting for this variation. A highly significant
correlation between progression rate and 17OHCS was seen,
even in patients not receiving ketoacids. The latter finding
appears to exclude the possibility that the correlation seen in all
27 subjects is a spurious consequence of effects of ketoacids to
alter glucocorticoid metabolism or renal handling of 17OHCS.
There have been several previous studies of endogenous
glucocorticoids in chronic renal failure. In children with chronic
renal failure, serum cortisol levels are reported to be normal
[28], but two reports have documented high morning levels of
free cortisol in plasma of adults with chronic renal failure [29,
301. Corticosteroid-binding globulin exhibits normal binding
affinity and capacity for cortisol in uremic plasma [311, but
cortisol binding to albumin is decreased [32]. In non-dialyzed
uremic adults, the urinary excretion of corticoid metabolites is
reported to be 65% of normal [331. Cortisol metabolism is
delayed in uremic subjects [34—37].
Fig. 1. Rate of change of glomerular
filtration rate plotted against
1 7-hydroxycorticosteroid excretion in 35
studies in 27 patients. The dashed lines
represent the linear regression slopes in each
of the three treatment groups and the solid
line represents the linear regression slope in
all 35 studies. All of the regressions shown
are statistically significant. Symbols are: (A)
protein restriction; (•) amino acids; (0) keto
acids.
The technique employed here for assessing glucocorticoid
production is relatively crude, in comparison with isotopic
measurement of cortisol production rate. However, 17OHCS
can be measured repeatedly and has been found to be superior
to free cortisol excretion, for example, in the diagnosis of
Cushing's syndrome [381. In 16 of the present patients, urinary
excretion rates of free cortisol were also measured, but were
not significantly correlated with either 17OHCS excretion rates
or rates of progression.
Several mechanisms by which corticoids might promote
progression can be envisaged. For example, glucocorticoids
stimulate Na-K-ATPase activity [39], which may play a role in
the progression of polycystic kidney disease [40] as well as
other types of renal disease. Glucocorticoids inhibit phospholi-
pase A, and suppress the production of prostaglandins by renal
interstitial cells [41], but in vivo they increase renal prostaglan-
din production [42], perhaps via lipolytic effects. Eicosanoids
cause constriction of glomerular mesangial cells, thereby low-
ering the glomerular ultrafiltration coefficient [43]. Glucocorti-
coids at 10 times physiologic dosage increase glomerular capil-
lary pressure in subtotally nephrectomized rats, thereby
augmenting glomerular injury, an effect prevented by the ad-
ministration of angiotensin-converting enzyme inhibitors [44].
Glucocorticoids may increase proteinuria in patients with
chronic renal disease [45—47], However, it should be noted that
the 17-hydroxycorticosteroid excretion rates observed in the
present study are all within (or in a few cases below) the normal
range, defined in this laboratory as 2 to 9 mg/day. Hence steroid
effects seen only at pharmacologic dosage may not be relevant
to the present relationship. Obviously endogenous glucocorti-
coids do not damage the normal kidney.
Variations within the normal range of glucocorticoid activity
have been shown to have profound effects on protein turnover.
Simmons et al [211 found an increase in proteolysis in human
subjects during infusion of sufficient cortisol to increase the
plasma level fourfold. Legaspi et al [22] reported that release of
essential amino acids from the human forearm increased four-
fold on infusing enough cortisol to raise plasma cortisol less
0
0 0
0
2 3 4 5 6 7 8 9 10 11 12
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Table 4. Correlation matrix between selected variables
y x1 x3 x6 x7 x9 x11 x12
x1
x3 0.36a 040b
x6 —0.11 0.39a Q35a
x7 —0.18 —0.24 —0,26
x9 —0.24 0.34a 0.13 0.15 0.07
x11 0.55' Ø35 0.03 —0.16 0.32a
x12 —0.31 Ø47C 0.51 0,58d —0.09 0.35a 0.14
x19 —0.06 0.17 —0.11 0.49c 0.23 —0.13 —0.10
Variables are: y, progression, mI/mm/month; x1, 17OHCS excretion, mg/day; x3, average glomerular filtration rate, mi/mm; x6, urinary urea N,
g/day; x7, serum calcium times phosphorus, mg2/d12; x9, serum uric acid, mg/dl; x11, serum triglycerides, mg/dl; x12, phosphaturia, mg/day; x19, x1/
x3.aP < 0.05
b P < 0.02
cP < 0.01
d P < 0.001
Table 5. Comparison of variables by treatment groups
Treatment group
(1) (2)
Mild Essential (3)
protein amino Keto
restriction acids acids
N=4 N=15 N=16 P
GFR mI/mm 16 13 8 NS
Rate of change of GFR mi/mm/month —0.352 —0.275 —0.171 NS
Serum
calcium x phosphorus mg2/d12 39 38 42 NS
alkaline phosphatase lU/liter 88 99 105 NS
uric acid mgldl 8.1 7.2 7.8 NS
cholesterol mg/dl 214 211 187 NS
triglycerides mg/dI 205 177 190 NS
24-hr urinary excretion of:
17-hydroxycorticosteroids mg 5.29a , 13b 3.1 1C <0.05
17-hydroxycorticosteroids/GFR ratio 0.36 0.40 0.52 NS
phosphate mg 5.58 4.27 3.42 NS
urea N g 9.02a 523b 517b <0001
proteing 3.34 2.25 1.57 NS
Mean arterial pressure mm Hg 109 105 105 NS
a.b.c Means with differing superscripts differ significantly at the P level shown by analysis of variance.
than fourfold. Clark [481 noted that adrenalectomized rats retain
more dietary nitrogen than sham-operated controls. How pro-
tein turnover and progression might be related is not clear.
Conceivably, the reportedly beneficial effect of protein re-
striction alone on the progression of chronic renal failure [8]
may also be related to lower glucocorticoid production. A high
protein intake has been reported to increase plasma cortisol
throughout the day in normal subjects [49], and protein-con-
taining midday meals stimulate cortisol secretion [50, 51]. In
normal subjects as well as in the patient studies reported in
Table S here, we have confirmed that protein restriction reduces
daily 17-hydroxycorticosteroid excretion (unpublished data).
Suppression by ketoacids of glucocorticoid production, at
least in patients with chronic renal failure, is strongly suggested
by these data. Whether such an effect is demonstrable in normal
subjects remains to be determined, as well as whether suppres-
sion of secretion of adrenocorticotrophic hormone or cortico-
tropin-releasing hormone occurs. Since we have previously
found that 2-ketoisocaproate, the analogue of leucine, spares
nitrogen in fasting [18, 19] and post-operative man [20], it is
Table 6. Multiple regression analysis of factors determining
progression rate, using 17OHCS factored by GFR
Variable b
Partial
r2
Model
r2 P
Serum —0.0010 0.341 0.341 0.0002
triglycerides
mg/dI
Polycystic kidney —0. 1998 0.115 0.455 0.0142
disease
Ketoacid therapy 0.1489 0.086 0.541 0.0222
I7OHCS/GFR —0.2123 0.059 0.600 0.0433
likely that this component of the mixture of ketoacids used here
is the one responsible for inhibiting glucocorticoid production.
If so, slowing of progression might be induced by this com-
pound alone. The present data are not sufficient to establish the
component responsible for the effects observed, nor the time
course of the effect. However, Figure 2 suggests that both the
onset and offset of this effect require more than a few days. This
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Fig. 2. Sequential measurements of
I 7-hydroxycorticosteroid excretion in a patient
changed from an amino acid supplement to
a ketoacid supplement and then changed
back twice. Mean values for 17-
hydroxycorticosteroid excretion in each
period are shown by the horizontal lines.
Hormone excretion is lower on ketoacids.
Table 7. Effect of changing from an essential amino acid supplement
(AA) to a ketoacid supplement (KA) or vice versa, without change in
diet, on urinary 17-hydroxycorticosteroids
Urinary 17-hydroxycorticosteroids
mg/day
Subject Sequence On AA On KA
3 AA—KA 5.47 2.68
4 AA—KA 3.65 1.75
4 KA—AA 2.48 1.75
4 AA—KA 2.48 1.98
6 AA-KA 4.40 2.90
6 KA-AA 3.40 2,90
9 AA—KA 5.25 3.65
10 AA—KA 3.30 3.18
11 KA—AA 2.40 2.20
18 AA—KA 2.90 2.17
19 AA—KA 3.15 4.35
22 AA—KA 6.77 5.60
25 AA—KA 3.30 2.43
26 AA—KA 4.13 3.74
Difference,AA - KA
2.79
1.90
0.73
0.50
1.50
0.50
1.60
0.12
0.20
0.73
—1.20
1.17
0.87
0.39
Mean 0.84
SEM 0.25
P < 0.005
would be consistent with, and a possible explanation of the
"carry-over effect" on nitrogen balance we have previously
noted when ketoacids are withdrawn [18, 191.
If glucocorticoid production contributes to the progression of
chronic renal failure, other measures that suppress the produc-
tion of these hormones could slow or arrest progression.
Several drugs are known to reduce glucocorticoid production or
receptor binding [52—54].
The weak but statistically significant correlation between
17OHCS and GFR (r2 = 0.16, Table 4) raises a question as to
whether part of the relationship depicted in Figure 1 is attrib-
utable to this interdependence, since there was also a weak but
significant correlation between progression rate and GFR (r2
0.13, Table 4). Factoring 17OHCS by GFR should eliminate this
potential source of error. When this was done, 17OHCS/GFR
was still a significant determinant of progression (Table 6).
Also, 17OHCS, measured an average of six times per study, fell
progressively in only two out of 35 studies. These observations
appear to eliminate this concern.
It is also doubtful that 17OHCS/GFR is a better measure of
glucocorticoid production than is 17OHCS alone. Plasma cor-
tisol levels, measured before lunch at noon in 14 of these
patients, were not different in those receiving ketoacids from
those receiving amino acids, nor different from normal, and
were also not correlated with progression rate (unpublished
observations). But meal-induced fluctuations and diurnal vari-
ations in cortisol levels [50, 51] would not be detected by this
sampling technique.
The other regressors that appeared to be significant in this
secondary analysis (Table 4) are of interest, particularly triglyc-
erides. High levels of serum triglycerides are reported to be
associated with progressive glomerular sclerosis in Dahl salt-
sensitive rats [101. There was a highly significant correlation
between serum triglyceride level alone and progression rate (r2
= 0.34, Table 4). These observations raise the possibility that
dietary manipulations designed to combat hypertriglyceridemia
might slow progression.
More rapid progression in the four patients with polycystic
kidney disease, also revealed by the secondary analysis (Table
6), is unexpected, and requires confirmation. Finally, the
slower progression associated with ketoacid therapy in this
secondary analysis suggests either that ketoacids exert an effect
on progression not reflected in 17OHCS/GFR, or (more likely)
that 17OHCS/GFR is less appropriate than 17OHCS as a
measure of glucocorticoid production.
It should be emphasized that the absence of correlations
between progression rate and other variables, such as serum
cholesterol, proteinuria, or mean arterial pressure does not
establish that these factors do not contribute to progression,
because the distribution of values of these variables may have
been too restricted to test such hypotheses adequately.
In conclusion, these results identify a highly significant
0 2 4 6 8 10
Months
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correlation between glucocorticoid production and rate of pro-
gression of chronic renal failure. The explanation of this corre-
lation and the mechanism by which endogenous corticoids may
contribute to progression remain to be elucidated.
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